InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
- InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function
- With neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgency
- InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families
InMed Pharmaceuticals (NASDAQ: INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids” (https://nnw.fm/vBFD2).
This international patent application specifies a rare cannabinoid that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, and others – by providing neuroprotection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function.
Dr. Eric Hsu, Senior VP Pre-Clinical Research & Development at InMed, described as encouraging the data demonstrating the potential for using a rare cannabinoid to enhance neuronal function and offer neuroprotection to treat neurodegenerative diseases.
“This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs,” continued Hsu.
According to the Harvard NeuroDiscovery Center, 5 million Americans currently suffer from Alzheimer’s Disease, 1 million from Parkinson’s Disease, 400,000 from multiple sclerosis (“MS”), 30,000 from Lou Gehrig’s Disease, and a further 30,000 from Huntington’s Disease. In addition, the center estimates that if left unchecked, three decades from now, more than 12 million Americans will suffer from neurodegenerative diseases, which primarily strike in mid- to late-life (https://nnw.fm/5zBxl). Globally, 135 million people are expected to be affected by Alzheimer’s disease alone by 2050, up from 40 million in 2015.
Neurodegenerative diseases are also projected to increase the individual, social, and financial burden of taking care of the patients. For instance, the projected economic impact of Alzheimer’s Disease in the United States alone is expected to reach about $1 trillion per year in 2050, according to the 2017 G7 Academies’ Joint Statements (https://nnw.fm/yMIQl). Based on these factors, the Harvard NeuroDiscovery Center notes that finding treatments and cures is a matter of increasing urgency. InMed’s patent application is, therefore, a promising start.
The application expands InMed’s patent portfolio, which currently includes twelve patent families, and demonstrates its commitment to pharmaceutical programs and the potential of rare cannabinoids in medicine. Furthermore, being an international patent law treaty, the PCT provides InMed with a unified procedure for filing patent applications to protect its invention in each of the 153 member countries.
Notably, the rare cannabinoid that forms the basis of the PCT is new to InMed’s portfolio. This showcases the company’s continued commitment to researching the therapeutic benefits of rare cannabinoids as well as producing rare cannabinoids for various uses.
With more than 140 rare cannabinoids that occur in low amounts in the cannabis plant, InMed observes that the cost of extracting sufficient quantities can be prohibitive. Even so, the company has unparalleled cannabinoid manufacturing expertise, anchored in three manufacturing approaches – biosynthesis, chemical synthesis, and IntegraSyn(TM) (https://nnw.fm/1kZgV) – that gives it complete flexibility to select the most suitable, cost-effective method to produce a high-quality and pure rare cannabinoid fit for the intended purpose.
Importantly, BayMedica, InMed’s most recent acquisition, is continuing to develop an expanding library of patentable, new cannabinoid analogs targeting diverse clinical applications.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function
- With neurogenerative diseases affecting millions worldwide and the cost of treating patients expected to rise in the future, finding treatments and cures is a matter of increasing urgency
- InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families
InMed Pharmaceuticals (NASDAQ: INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids” (https://nnw.fm/vBFD2).
This international patent application specifies a rare cannabinoid that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, and others – by providing neuroprotection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function.
Dr. Eric Hsu, Senior VP Pre-Clinical Research & Development at InMed, described as encouraging the data demonstrating the potential for using a rare cannabinoid to enhance neuronal function and offer neuroprotection to treat neurodegenerative diseases.
“This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs,” continued Hsu.
According to the Harvard NeuroDiscovery Center, 5 million Americans currently suffer from Alzheimer’s Disease, 1 million from Parkinson’s Disease, 400,000 from multiple sclerosis (“MS”), 30,000 from Lou Gehrig’s Disease, and a further 30,000 from Huntington’s Disease. In addition, the center estimates that if left unchecked, three decades from now, more than 12 million Americans will suffer from neurodegenerative diseases, which primarily strike in mid- to late-life (https://nnw.fm/5zBxl). Globally, 135 million people are expected to be affected by Alzheimer’s disease alone by 2050, up from 40 million in 2015.
Neurodegenerative diseases are also projected to increase the individual, social, and financial burden of taking care of the patients. For instance, the projected economic impact of Alzheimer’s Disease in the United States alone is expected to reach about $1 trillion per year in 2050, according to the 2017 G7 Academies’ Joint Statements (https://nnw.fm/yMIQl). Based on these factors, the Harvard NeuroDiscovery Center notes that finding treatments and cures is a matter of increasing urgency. InMed’s patent application is, therefore, a promising start.
The application expands InMed’s patent portfolio, which currently includes twelve patent families, and demonstrates its commitment to pharmaceutical programs and the potential of rare cannabinoids in medicine. Furthermore, being an international patent law treaty, the PCT provides InMed with a unified procedure for filing patent applications to protect its invention in each of the 153 member countries.
Notably, the rare cannabinoid that forms the basis of the PCT is new to InMed’s portfolio. This showcases the company’s continued commitment to researching the therapeutic benefits of rare cannabinoids as well as producing rare cannabinoids for various uses.
With more than 140 rare cannabinoids that occur in low amounts in the cannabis plant, InMed observes that the cost of extracting sufficient quantities can be prohibitive. Even so, the company has unparalleled cannabinoid manufacturing expertise, anchored in three manufacturing approaches – biosynthesis, chemical synthesis, and IntegraSyn(TM) (https://nnw.fm/1kZgV) – that gives it complete flexibility to select the most suitable, cost-effective method to produce a high-quality and pure rare cannabinoid fit for the intended purpose.
Importantly, BayMedica, InMed’s most recent acquisition, is continuing to develop an expanding library of patentable, new cannabinoid analogs targeting diverse clinical applications.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
